used in this paper. Spasticity is seen as a "motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks (phasic stretch reflex), resulting from hyperexcitability of the stretch reflex" (Lance, 1980, p. 485) . Muscle tone, whether it be high, low, or normal, is "the sensation of resistance that is encountered as a joint is passively moved through a range of motion" (Lance & McLeod, 1981, p. 128) .
One aim of therapy for children who have cerebral palsy or other neurological impairments is to manage spasticity and hypertonia when it interferes with optimal engagement of the child in appropriate occupations. Conventional therapeutic management of spasticity and hypertonia in children with cerebral palsy has involved various techniques including splinting, casting, facilitation of posture and movement, and passive stretching (e.g., Law et al., 1991 Law et al., , 1997 . More recently, BtA has been used as an adjunct to therapeutic techniques in an attempt to reduce focal spasticity, increase range of motion, improve agonist-antagonist balance, improve function, and delay the need for orthopedic procedures. BtA acts at the neuromuscular junction by inhibiting the release of the neurotransmitter acetylcholine (Graham, 2000) . When injected into selected muscles, BtA produces a dose-dependent chemical denervation resulting in reduced muscular activity. Subsequent sprouting of new nerve terminals leads to reinnervation, or restoration of the original terminal. Thus the function of the original terminal is eventually restored, which results in the recovery of the affected muscles (de Paiva, Meunier, Molgo, Aoki, & Dolly, 1999) .
For occupational therapists, the integration of BtA into traditional practice may provide a unique opportunity. If BtA injection provides a window of reduced spasticity and hypertonia, this may enable occupational therapists, utilizing purposeful activities (i.e., those that have meaning to the child) to assist children to learn motor skills and gain selective motor control. Occupational therapists have the ability to identify the specific performance areas, components and contexts that may (or may not) enable a child to engage in meaningful occupations such as play or schoolwork (Kramer & Hinojosa, 1999) . The combination of a reduction in spasticity through medical management and improved selective motor control through therapy has the potential to maximise the functional independence and improve the occupational performance of children with cerebral palsy.
Following a brief summary of the history of BtA use, this paper will present the results of a comprehensive review of the research literature regarding the use of BtA in the management of upper-limb spasticity to improve function in children with cerebral palsy. The clinical implications for occupational therapy practice and potential for the use of BtA as an adjunct to traditional treatment approaches are discussed.
History of Botulinum Toxin Use
BtA is marketed in a number of countries under the trade names Botox ® (Allergan) or Dysport ® (Speywood), and was first used therapeutically in humans in 1980 (Gooch & Sandell, 1996) . The initial success of BtA in the treatment of strabismus and blepharospasm (Gooch & Sandell) , along with minimal side effects has led to the clinical use of BtA for denervation of muscles in a number of neurological and non-neurological disorders (Jankovic & Brin, 1997) . The effect of BtA is not immediate; the response delay varies from 12 hours to 7 days (Forssberg & Tedroff, 1997) . Clinically useful reduction of muscle activity usually lasts 12-16 weeks and the effects appear to be dose-dependent and largely or completely reversible .
BtA treatment of focal spasticity in children with cerebral palsy is considered safe and effective (Mohamed, Moore, & Rosenbloom, 2001) . Local adverse effects of BtA may include pain at the injection site, excessive weakness in the injected muscle, or unwanted weakness in the adjacent muscles. Systemic effects, although rare, may include transient flu-like symptoms, anaphylaxis, or excessive or generalized mild weakness (Carr, Cosgrove, Gringras, & Neville, 1998) . Resistance to BtA, characterized by the absence of any beneficial effect, has occasionally been observed and has been attributed to antibody formation against the toxin (Brin, 1997) . Treatment recommendations have included a 3-month minimum interval between injections to avoid the formation of neutralizing antibodies (Delgado, 1999) , however, improved purification of the drug may minimize the problem of antibody formation (Chait, de Augier, Theron, & Bleloch, 2003) .
BtA is thought to be effective as it allows a prolonged stretch to muscle fibers (by concurrent splinting or active antagonists) that results in the muscle physically lengthening (Wall et al., 1993) . This muscle lengthening suggests theoretically that BtA may decrease or delay fixed deformity and thus the need for early surgery in children (Kirschner, Berweck, Mall, Korinthberg, & Heinen, 2001) .
In 1993, Koman, Mooney, Smith, Goodman, and Mulvany reported successful use of BtA injections in the lower limbs in children with cerebral palsy, and BtA is now approved in Australia for the treatment of equinus deformity in children with cerebral palsy more than 2 years of age. As BtA is now an established intervention for the lower limb, attention has turned to the impact of BtA on the upper limb. Of particular interest to occupational therapists is whether BtA can provide the opportunity for improved occupational performance in children with neurological impairments.
Methods
A comprehensive search of electronic databases (MEDLINE 1966 -October, Week 5 2003 CINAHL 1982 -October 2003 Embase 1988 (Law et al., 1998) and level of evidence determined using the National Health and Medical Research Council guidelines (National Health and Medical Research Council, 2000) .
Results of the Literature Review
The electronic database search identified two randomized controlled trials (RCTs), nine prospective single-group study designs, four case studies, and a number of abstracts and letters to the editor, all evaluating the outcomes of BtA injection to the upper limb. The two level II studies (Corry, Cosgrove, Walsh, McLean, & Graham 1997; Fehlings, Rang, Glazier, & Steele, 2000 , are RCTs and represented the highest level of evidence published to date. Both are presented in detail in this paper in Table 1 and the text. The 13 level IV studies (nine prospective single-group designs and four case studies) are listed in Table 2 . These studies all lack control group comparisons thus limiting their validity and some have significant methodological flaws. The results of the highest quality prospective singlegroup design studies are summarized in Table 3 . Table 1 provides a comparative summary of both the Corry et al. (1997) and Fehlings et al. (2000) trials. Corry et al. conducted a randomized, double-blind, controlled trial to test two hypotheses: "that botulinum toxin-A injection into the flexor muscles of the arm and forearm can reversibly decrease muscle tone, increase range of motion and improve the function of the hemiplegic upper limb" (p. 185) compared with a normal saline solution, and "that the response of large muscle groups to BtA injection is clinically detectable" (p. 185).
Findings From the RCTs
Despite the very small sample, Corry et al.'s (1997) main hypothesis was confirmed using valid and reliable outcome measures: BtA had a detectable clinical effect of reducing muscle tone after injection into the forearm muscles in spastic cerebral palsy. The results regarding range of motion were variable. The authors report some improvement in functional outcomes; however, the lack of validated measures limits the interpretation of this finding. The authors present their results as group median scores, and although the reader cannot estimate 95% confidence intervals from these, the differences between groups in functional outcomes appear to represent minimal clinically important change.
Although the positive results of this small RCT were limited when evaluated by group, the authors did report that some individuals experienced positive responses to BtA as measured by one or more of the outcome assessments. Corry et al. (1997) also found that those participants with weakness, poor control, or fixed contracture did not respond well to intervention with BtA. Following completion of the trial, all participants in the control group were offered BtA injection and Corry et al. also reported summarized results (using nonblind assessment) for the whole group. As a group, the 14 participants also demonstrated a statistically significant decrease in wrist-resonant frequency, increased elbow extension, decreased wrist tone (modified Ashworth), and improved grasp score at 12 weeks. Fehlings et al. (2000) in a single-blind, randomized, controlled trial, investigated whether "BtA injections into the upper extremities of children with spastic hemiplegia improve (d) upper extremity function" (p. 331). Fehlings et al. (2000) concluded that their trial supported the use of BtA to improve quality of movement of the arm and functional ability of children with hemiplegic cerebral palsy. Improvements in function were present despite a weaker grip after BtA. Fehlings et al. (2000) included appropriate measures of upper-limb function (Pediatric Evaluation of Disability Index [PEDI], Quality of Upper Extremity Skills Test [QUEST] ) and the QUEST total score increased significantly. Post hoc analyses, however, suggested that the greatest effect occurred in the upper-limb weight-bearing subtest and that the other subtests-dissociated movements, grasp, and protective extension-did not demonstrate significant differences between groups. Analyses of PEDI raw scores for the self-care functional skills domain showed a statistically significant difference between groups. As the author provided group means, 95% confidence intervals can be estimated to guide the clinical interpretation of this result. At 6 months, the treatment group scores were on average 4.13 (+/-1.13) points higher than the control group (in a potential range of 0-73 points) suggesting that the treatment group gained a small but potentially clinically important difference in outcome over the control group.
Interestingly, there were also positive changes in function and a decline in muscle tone in the control group, which received more occupational therapy sessions (mean sessions = 16.07 ± 7.6) than the BtA group (mean = 11.93 ± 6.89). Although the difference in session numbers was not statistically significant, it does raise the question of whether improvement in the control group may have been influenced by an increased number of therapy sessions. Although a statistically significant change in function was found, favoring the treatment group, Fehlings et al. (2001) also highlighted that only 9 of 14 individuals who received BtA improved. That is, not everyone benefited. Additional analyses were undertaken on treatment group data in order to determine which characteristics might predict positive outcome. The data were analyzed as groups of nonresponders and responders, based on a 10% increase on QUEST scores. Grip strength was found to be a statistically significant predictor of outcome with responders having higher baseline grip strength than nonresponders. Younger age was the only other variable to show some relationship with better outcome.
The evidence from these two trials was promising with both trials suggesting that intramuscular injections of BtA resulted in short-term outcomes by reducing muscle tone, increasing active range of motion in Corry et al. (1997) , and demonstrated positive changes in quality of upper-limb movement and self-care skills in children with at least moderate spasticity in Fehlings et al. (2000) . Table 3 provides a comparative summary of six of the nine single-group studies that were located. These six studies were selected as they presented sufficient detail to appraise methodological quality and represented those with the least number of internal biases related to lack of blinding of assessors and choice of outcome measures. Although these six studies provided some evidence of worth, a number of limitations remain. None used random selection of patients, which introduced a potential bias in patient selection, nor were there any control groups for comparison. One study had historical limitations related to data collected over a prolonged period (Friedman, Johnston, & Daffner, 2000) , which may have resulted in changed intervention techniques. In addition, with the exception of Hurvitz, Conti, and Brown (2003) , poor control of extraneous variables, such as additional interventions, and the fact that only a few used validated measures of upper-limb or hand function affects the usefulness of many of the findings. The positive and useful elements of these studies included the generally full descriptions of the participants and the BtA component of the study including injection site, localization method, dosage, and muscles injected. These details allow comparison between papers and help the reader refer findings to a particular clinical population or individual. All reported on measures additional to the nonvalidated functional outcome measures, such as range of motion and muscle tone assessment, which have demonstrated validity and reliability. Most of the studies met the purpose they were designed for, that is, preliminary investigations, and made cautious or appropriate conclusions related to their findings. The positive findings suggested that most children experienced a decrease in tone at least for a short period. There was variable response in range of motion, and grip strength tended to decrease initially. Functional outcomes were poorly represented with the authors typically relying on anecdotal or unvalidated outcomes, with the exception of Yang, Kao, Chan, and Chen (2003) and Hurvitz et al. (2003) . Yang et al. present a particularly strong paper with 15 children who act as their own controls through repeated baseline measures. Using valid, reliable outcomes, Yang et al. demonstrated significant improvements in functional skills. Other studies also suggested that some children respond positively to BtA. Overall, those children with dynamic hypertonicity, intact sensation, and some voluntary movement before injection had the most positive responses in terms of reduced spasticity and improved functional outcomes.
Outcomes From the Prospective Single-Group Design Studies

Discussion
In the lower limb, injection of BtA has been demonstrated to significantly affect spasticity and hypertonia and to provide an opportunity for development of improved lowerlimb functional outcomes, such as improved gait (Boyd & Hays, 2001 ). In the upper limb, the evidence of two RCTs and 13 lower-level studies found that high muscle tone can be temporarily reduced following BtA injection and that there is the potential for improved functional outcome. A number of authors have suggested that children who have a favorable functional response to BtA tend to be those with at least moderately high muscle tone (Corry et al., 1997; Fehlings et al., 2000) , without fixed contracture (Arens, Goldschmidt, & Leary, 1997; Corry et al.) , preserved grip strength (Fehlings et al., 2001) , some distal voluntary control (Fehlings et al., 2000) , intact sensation and motivation to participate in postinjection training (Autti-Ramo, Larsen, Peltonen, Taimo, & von Wendt, 2001 ).
In the follow-up paper to their RCT, Fehlings et al. (2001) showed that the children who had a positive functional response to BtA had significantly higher baseline grip strength (all ≥ 60 mmHg) and tended to be younger. In contrast, Friedman et al. (2000) found age was not significantly related to reductions in tone after BtA. The small samples and variable responses of children receiving BtA suggests that further investigations of specific baseline characteristics, including age and severity of cerebral palsy, will be important to assist the clinical determination of which children are likely to experience positive functional gains.
BtA injections in the upper limb have fairly consistently resulted in reduced tone, however, a reduction of tone is probably not sufficient to improve function in the upper limb. Forssberg and Tedroff (1997) postulated that by reducing muscle tone, a child might be able to develop "normal" motor coordination that would otherwise be prevented by hypertonia and spasticity and secondary musculoskeletal malformations. This hypothesis neglected to consider the many aspects that limit or influence "normal" motor coordination. As Hurvitz, Conti, Flansburg, and Brown (2000) state, "In spastic conditions in which there has been long term non-usage of a limb, a reduction in muscle tone is a necessary but insufficient condition for motor improvement" (p. 1413).
In theory, by reducing spasticity and hypertonia, BtA assists in establishing a balance between agonist, antagonist, and synergistic muscles. In conjunction with appropriate therapy techniques, this improved muscle balance may facilitate improved limb mobility and the development of selective motor control. As a result, more effective interpretation of tactile, proprioceptive, and vestibular sensory input may enable the development of more complex neural patterns, thereby improving motor response. Thus, it is perhaps the combined effect of BtA and therapy that may contribute to improvements in function such as those found in the studies by Fehlings et al. (2000) and Yang et al. (2003) . These two studies stand out as ones that included valid and appropriate outcome measures of function, ongoing therapy, and at least 15 participants, perhaps providing just enough power to detect differences where they lie.
The primary aims of the studies located related directly to the effect of BtA as an antispasticity medication newly used in the upper limb and as such have provided little information on concurrent therapies. In some studies the children were described as receiving no therapy (Hurvitz et al., 2000 (Hurvitz et al., , 2003 Mall, Heinen, Linder, Philipsen, & Korinthenberg, 1997 ), unspecified therapy (Autti-Ramo et al., 2000 Freidman et al., 2000; Yang et al., 2003) or there was no information at all on whether therapy was provided or not (Denislic & Meh, 1995; Gooch & Sandel, 1996) . Four of the papers, however, provided some information on concurrent therapies with some children receiving splinting Mall et al., 1997; Wall et al., 1993) or activities to strengthen the limb or develop skills of daily living (Fehlings et al., 2000) . Autti-Ramo et al. (2001) , provided the most comprehensive description of postinjection therapy in their clinical paper. They reported that children undertook intense home therapy programs, continued with their current regime of individual occupational therapy, and received splinting. Home programs focused on limb use during daily tasks and play, whereas therapy focused on "specific training for learning new functional abilities" (p. 141) based on preinjection goals. Splinting included neoprene soft splints or thermoplastic night splints or both. As many children's function appeared to be limited by reduced sensation, Autti-Ramo et al. (2001) also reported on the developing use of vibration and electrical stimulation of weak antagonists to assist the children during functional tasks. While Autti-Ramo et al. (2001) appear to have provided a good framework for postinjection therapy, the efficacy of this therapy is yet to be tested empirically.
As BtA provides a relatively short interval of effect, investigations of postinjection therapy intensity are also required. Both Fehlings et al. (2000) and Corry et al. (1997) observed that the effect of BtA continued up to 6 months after injection, which is much longer than the effects of the neuromuscular blockade that disappears, on average, at 3 months. While the differences were not significant, the Fehlings et al. (2000) control group, who received slightly more therapy, also showed positive trends for change in function. Whether this trend was related to increased intensity, a change in therapy focus as community therapists were provided with therapy plans, or an increased attention to upper-limb treatment is unknown.
There appears to be some consensus that BtA in the upper limb will be most effective when combined with therapy (e.g., Hurvitz et al., 2000 Hurvitz et al., , 2003 Yang et al., 2003) . Indeed, Graham (2000) postulated that "the use of BtA injections in the hemiplegic upper limb, combined with intelligent use of occupational therapy and splinting, should reduce deformity and improve function for many children" (p. 302). For this statement to be supported, further randomized controlled trials, using valid and responsive functional outcome measures, are needed. However, it
is not yet clear what type of therapy will be required. One recent abstract publication reporting early analyses suggested a positive impact of occupational therapy in conjunction with BtA. This abstract alluded to evidence of cortical motor reorganization as measured by functional magnetic resonant imaging in a small group of children who received BtA plus occupational therapy training versus those who received training alone (Boyd et al., 2002) .
Although it is encouraging to see evidence of one RTC investigating the effect of therapy after BtA (Boyd et al., 2002) , further work is required to establish what specific therapy will enhance functional outcomes and prolong the beneficial effects of BtA. Will traditional occupational therapy interventions, including such elements as facilitation of movement or task training, in combination with BtA effectively facilitate the development of selective motor control and overcome a learned non-use? Or, as has been suggested, will it be BtA plus splinting (Corry et al., 1997) , constraint induced movement therapy (Boyd, Morris, & Graham, 2001) , or occupational therapy and electrical stimulation as biofeedback to weak antagonists (Autti-Ramo et al., 2001 ) that will be required to maximize the functional benefits of BtA injections to the upper limb? Clearly more research evidence is required, and it behooves occupational therapists, with their upper-limb training expertise, to be active members of future research endeavors.▲
